Clinical Trials
Methodology & AI Transparency ⓘ
Clinical Trials Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical trials are research studies that test how well new medical approaches work in people.
- 2 Real-world patient consensus: Clinical coding for Clinical Trials uses ICD-10 N41.3 across Urology & Prostate specialty care.
- 3 Typical cash cost range: Primary evaluation for Clinical Trials incorporates urinalysis/urine culture [Clinical Trials N41.3] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Clinical Trials: IPSS Urinary Symptom in Clinical Trials (N41.3: Score) (0 – 7 (mild symptoms) (N41.3)) and Urinalysis & Post-Void in Clinical Trials (N41.3: Residual (PVR)).
Ask our AI Specialists anything about Clinical Trials
What Is Clinical Trials?
Clinical trials are research studies that test how well new medical approaches work in people. Each study answers scientific questions and tries to find better ways to prevent, screen for, diagnose, or treat a disease. Clinical trials may also compare a new treatment to a treatment that is already available. Every clinical trial has a protocol, or action plan, for conducting the trial. The plan describes what will be done in the study, how it will be conducted, and why each part of the study is necessary. Each study has its own rules about who can take part. Some studies need volunteers with a certain disease. Some need healthy people. Others want just men or just women.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in urology & prostate, Clinical Trials (N41.3) involves uropathogenic bacterial mucosal in Clinical Trials (N41.3: adherence (cystitis) or). Cross-referenced with NIH MeSH (Clinical Trials as Topic), progression correlates with shifts in IPSS Urinary Symptom in Clinical Trials (N41.3: Score) (0 – 7 (mild symptoms) (N41.3)).
Common Symptoms & Clinical Signs
- • Make sure that the study is ethical
- • Protect the rights and welfare of the participants
- • Presentation of Clinical Trials (N41.3): sudden severe flank-to-groin in Clinical Trials (N41.3: colicky pain caused)
- • Secondary Clinical Trials clinical sign: weak, hesitant, or in Clinical Trials (N41.3: intermittent urinary stream)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Clinical Trials Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N41.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Clinical Trials (N41.3: Score) | 0 – 7 (mild symptoms) (N41.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Clinical Trials (N41.3: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (N41.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total PSA & in Clinical Trials (N41.3: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (N41.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Clinical Trials
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Ziihera (Zanidatamab-Hrii) Ziihera • RxCUI 2698212 | Bispecific HER2-directed Antibody | 93% | $1.7000 | $ 130.90 /mo |
| Icotyde (Icotrokinra) Icotyde • RxCUI 2739042 | FDA Prescription Therapeutic Agent | 77% | $280.0348 | $ 640.00 /mo |
| Tradjenta (Linagliptin) Tradjenta • RxCUI 1100702 | Dipeptidyl Peptidase 4 Inhibitor | 88% | $16.7954 | $ 640.00 /mo |
| Kimmtrak (Tebentafusp) Kimmtrak • RxCUI 2590754 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager | 80% | $1.7100 | $ 131.62 /mo |
| Azelastine Hydrochloride and Fluticasone Propionate (Azelastine Hydrochloride, Fluticasone Propionate) Azelastine Hydrochloride and Fluticasone Propionate • RxCUI 1797847-B45802066 | Corticosteroid | 75% | $2.0210 | $ 154.01 /mo |
| Butal/Apap/Caff Butal/Apap/Caff Generic • RxCUI RXN-72189441-3137 | Barbiturate | 80% | $3.1200 | $ 134.86 /mo |
| Anticoagulant Citrate Dextrose (Acd) Anticoagulant Citrate Dextrose (Acd) Generic • RxCUI RXN-09429001-3063 | Calculi Dissolution Agent | 93% | $2.0100 | $ 89.91 /mo |
| Hydroxyzine Atarax • RxCUI RXN-04049878-1903 | Antihistamine | 82% | $0.1326 | $ 5.59 /mo |
| Tobradex St (Tobramycin / Dexamethasone) Tobradex St • RxCUI 1011080 | Aminoglycoside Antibacterial | 84% | $46.6196 | $ 640.00 /mo |
| Kenalog-10 (Triamcinolone Acetonide) Kenalog-10 • RxCUI 1085750 | Corticosteroid | 74% | $2.3216 | $ 175.66 /mo |
| Clindamycin Phosphate Topical Solution USP, 1% Clindamycin Phoaphate Topical Solution USP, 1% • RxCUI RXN-21922002-2309 | Lincosamide Antibacterial | 89% | $0.1487 | $ 14.52 /mo |
| Pain Relieving Ointment Magic Cream • RxCUI 2752709 | Over-the-Counter Clinical Monograph | 81% | $0.0427 | $ 10.23 /mo |
| Doxyclycline Hyclate Doxycycline Hyclate • RxCUI RXN-68180654-3115 | Tetracycline-class Drug | 92% | $0.6934 | $ 36.58 /mo |
| Milnacipran Hydrochloride Savella • RxCUI RXN-33342372-1873 | Serotonin and Norepinephrine Reuptake Inhibitor | 89% | $2.7269 | $ 22.97 /mo |
| Prexxartan Prexxartan Generic • RxCUI RXN-76281155-2453 | Angiotensin 2 Receptor Blocker | 85% | $2.5700 | $ 112.58 /mo |
| Doxycyclate Hyclate (Doxycycline Hyclate) Doxycyclate Hyclate • RxCUI 1649988 | Tetracycline-class Drug | 74% | $0.1177 | $ 16.97 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Clinical Trials)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Testosterone Replacement Therapy on Lower Urinary Tract: What a 2,029-Participant Study Found In this meta-analysis of 14 clinical trials of TRT for LOH, the change in IPSS was similar among men receiving TRT versus placebo, suggesting that TRT treatment does not worsen LUTS among men with LOH. European urology • 2016-06-15 • Meta-Analysis | N = 2,029 | 99/100 | PMID 26874809 ↗ |
| New Insights on Glucagon-like peptide-1 receptor agonists and: What a 14,972-Participant Study Found The present meta-analysis does not suggest any increase in the risk of pancreatitis with the use of GLP-1RA. Diabetes research and clinical practice • 2014-02-15 • Meta-Analysis | N = 14,972 | 99/100 | PMID 24485345 ↗ |
| New Insights on Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the: What a 12,300-Participant Study Found GLP-1RAs triggered more gastrointestinal side effects than placebo, with no in-between difference. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2023-03-15 • Meta-Analysis | N = 12,300 | 99/100 | PMID 36579723 ↗ |
| New Insights on Efficacy of tadalafil in clinical: What a 321-Participant Study Found Tadalafil was effective in improving erectile function across a wide spectrum of ED patients including patients with various comorbid conditions. The journal of sexual medicine • 2005-07-15 • Meta-Analysis | N = 321 | 97/100 | PMID 16422847 ↗ |
| New Insights on Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due: What a 952-Participant Study Found Pooled data confirm the safety and tolerability of fezolinetant over 52 weeks. Advances in therapy • 2025-02-15 • Meta-Analysis | N = 952 | 97/100 | PMID 39739195 ↗ |
Clinical Trials Patient Community & “People Like Me” Threads
Filter Clinical Trials community threads and patient logs by age, biological sex, dosage, and treatment duration.